芪苈强心胶囊治疗老年AECOPD致中重度肺心病患者的疗效及安全性分析

摘要/Abstract

摘要： 目的探讨予以老年慢性阻塞性肺疾病急性加重期（AECOPD）致中重度肺心病（PHD）芪苈强心胶囊进行治疗的效果。方法选择本院2021年3月至2024年2月收治的老年AECOPD致中重度PHD患者88例作为研究对象,按随机数字表法分为两组,对照组实施常规治疗（44例）,观察组联合芪苈强心胶囊（44例）。持续治疗2周。对比两组临床疗效、心功能[左室射血分数（LVEF）、心脏指数（CI）、N末端B型钠尿肽前体（NT-proBNP）]、生活质量[COPD评估测试（CAT）量表、明尼苏达心衰患者生活质量调查问卷（MLHFQ）]以及治疗安全性。结果观察组临床总有效率为95.45%,高于对照组的81.82%,观察组治疗后LVEF、CI水平为（50.66±6.59）%、（3.19±0.65）L/min·m²,高于对照组的（45.43±6.17）%、（2.91±0.63）L/min·m²,NT-proBNP水平为（566.67±97.94）ng/L,低于对照组的（744.43±102.93）ng/L,CAT、MLHFQ量表评分为（11.65±2.71）分、（47.43±7.15）分,均低于对照组的（15.52±3.20）分、（54.56±8.21）分,差异有统计学意义（P<0.05）;两组治疗过程中均未出现不良反应。结论予以老年AECOPD致中重度PHD患者芪苈强心胶囊治疗,疗效显著,可有效改善其心功能,提升生活质量,且具有较好的治疗安全性。

关键词: 中重度肺心病, 慢性阻塞性肺疾病急性加重期, 芪苈强心胶囊, 临床疗效, 治疗安全性, 心功能

Abstract: Objective To investigate the efficacy of Qili Qiangxin capsules in the treatment of elderly patients with moderate or severe pulmonary heart disease (PHD) caused by acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods A total of 88 elderly patients with moderate or severe PHD caused by AECOPD who were admitted to our hospital from March 2021 to February 2024 were enrolled as subjects, and they were divided into control group and observation group using a random number table, with 44 patients in each group. The patients in the control group received conventional treatment, and those in the observation group received conventional treatment combined with Qili Qiangxin capsules. The course of treatment was 2 weeks. The two groups were compared in terms of clinical outcome, cardiac function (left ventricular ejection fraction [LVEF], cardiac index [CI], and N-terminal pro-brain natriuretic peptide [NT-proBNP]), quality of life (COPD assessment test [CAT] and Minnesota Living With Heart Failure Questionnaire [MLHFQ]), and treatment safety. Results The observation group had a significantly higher overall response rate than the control group (95.45% vs 81.82%, P<0.05). Compared with the control group after treatment, the observation group had significantly higher levels of LVEF (50.66%±6.59% vs 45.43%±6.17%, P<0.05) and CI (3.19±0.65 L/(min·m²) vs 2.91±0.63 L/(min·m²), P<0.05) and a significantly lower level of NT-proBNP (566.67±97.94 ng/L vs 744.43±102.93 ng/L, P<0.05). The observation group had significantly lower CAT and MLHFQ scores than the control group (CAT: 11.65±2.71 vs 15.52±3.20, P<0.05; MLHFQ: 47.43±7.15 vs 54.56±8.21, P<0.05). No adverse event was observed in either group during treatment.Conclusion Qili Qiangxin capsules have a marked clinical effect in elderly patients with moderate or severe PHD caused by AECOPD and can effectively improve cardiac function and quality of life, with a favorable safety profile.

Key words: Moderate or severe pulmonary heart disease, Acute exacerbation of chronic obstructive pulmonary disease, Qili Qiangxin capsules, Clinical effect, Treatment safety, Cardiac function

许鸿东, 吴贞. 芪苈强心胶囊治疗老年AECOPD致中重度肺心病患者的疗效及安全性分析[J]. 心血管病防治知识, 2024, 14(22): 39-42.

XU Hongdong, WU Zhen. Efficacy and safety of Qili Qiangxin capsules in treatment of elderly patients with moderate or severe pulmonary heart disease caused by acute exacerbation of chronic obstructive pulmonary disease[J]. Prevention and Treatment of Cardiovascular Disease, 2024, 14(22): 39-42.

参考文献

[1] 王高明,任重.芪苈强心胶囊联合无创通气治疗COPD合并肺源性心脏病的疗效[J].中国卫生标准管理,2022,13(19):152-156.
[2] 牛芳,唐素娟,尹振华.富马酸比索洛尔片联合噻托溴铵粉雾剂雾化吸入治疗慢性阻塞性肺疾病急性加重期并发肺源性心脏病患者的疗效[J].中国医师杂志,2023,25(7):1003-1007.
[3] 王福琴,刘政,李成伟,等.基于TCM-PRO-PHD量表的芪苈强心胶囊改善老年COPD致PHD稳定期患者生活质量的临床观察[J].世界中医药,2017,12(5):1011-1013,1017.
[4] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264.
[5] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.慢性肺源性心脏病基层诊疗指南(实践版·2018)[J].中华全科医师杂志,2018,17(12):966-969.
[6] 蔡睿,侯刚,王秋月,等.慢性阻塞性肺疾病评估测试对生存质量的评估价值研究[J].中国实用内科杂志,2011,31(11):847-849.
[7] 王晓楠,江莹,康晓凤,等.健康合作者量表汉化及在慢性心力衰竭患者中的信效度检验研究[J].中国全科医学,2022,25(4):497-504.
[8] 段林立,任妮,王冠理,等.STS治疗AECOPD合并慢性肺源性心脏病的有效性及安全性[J].广东医学,2023,44(11):1351-1356.
[9] 陶文婷,漆军华,敖丹.芪苈强心胶囊联合新活素对顽固性心衰的疗效及对miR-132,miR-155的影响[J].心血管康复医学杂志,2023,32(6):595-599.
[10] 冯超,蒋汉涛,樊官伟,等.芪苈强心胶囊降低慢性心力衰竭急性失代偿患者发生利尿剂抵抗风险的回顾性研究[J].中国全科医学,2024,27(21):2578-2585.
[11] 刘恒,杨亚楠,于祯,等.芪苈强心胶囊联合沙库巴曲缬沙坦治疗对冠心病心力衰竭患者心功能及血清因子水平的影响[J].临床和实验医学杂志,2023,22(9):910-914.
[12] 刘玉梅. 芪苈强心胶囊治疗老年慢性阻塞性肺疾病致中重度肺心病疗效观察[J].现代中西医结合杂志,2020,29(2):196-199.

[1]	谢明星. 冻干重组人脑利钠肽联合左西孟旦对急性失代偿性心衰患者心功能及效果分析[J]. 心血管病防治知识, 2024, 14(9): 45-46.
[2]	唐静, 吕梅蓉. 铜砭刮痧在急诊肝火上炎证高血压患者中的疗效观察[J]. 心血管病防治知识, 2024, 14(9): 47-50.
[3]	吕明芳. 质量控制理论的康复训练联合思维场干预在AMI患者术后的应用价值[J]. 心血管病防治知识, 2024, 14(9): 55-59.
[4]	郑丹, 张神爱. 康复护理对心肌梗死PCI术后患者心功能的影响分析[J]. 心血管病防治知识, 2024, 14(9): 67-69.
[5]	丁微. 路径化引导下心脏康复护理对急性心肌梗死PCI术后患者的影响[J]. 心血管病防治知识, 2024, 14(9): 86-89.
[6]	黄丹, 翁小清, 陈雪碧. 运动-心理-睡眠护理配合基于代谢当量的运动康复方案对老年心力衰竭患者心功能及效果分析[J]. 心血管病防治知识, 2024, 14(9): 117-119.
[7]	蒋鹏慧, 梁秋燕, 李春波, 邓春晓, 邱艳, 邓齐英, 成锦. 专科护士主导的慢性病团队管理模式在慢性心力衰竭护理的应用研究[J]. 心血管病防治知识, 2024, 14(9): 120-123.
[8]	苏喜鸿. 基于快速康复理念的多学科协作康复运动模式用于心脏术后患者护理中的效果[J]. 心血管病防治知识, 2024, 14(9): 138-140.
[9]	刘磊. 芪苈强心胶囊与马来酸依那普利共治对慢性心衰患者心功能及机体炎症指标的影响[J]. 心血管病防治知识, 2024, 14(8): 32-34.
[10]	任文懋. 沙库巴曲缬沙坦钠在高血压冠心病患者PCI术后的作用及对心功能的影响[J]. 心血管病防治知识, 2024, 14(8): 35-37.
[11]	童慧玲, 陈亮. 恩格列净联合沙库巴曲缬沙坦对慢性心力衰竭合并2型糖尿病患者心功能的影响[J]. 心血管病防治知识, 2024, 14(8): 44-47.
[12]	刘丽雅. 心血管科专病一体化管理模式应用于老年冠心病患者中的综合评价[J]. 心血管病防治知识, 2024, 14(8): 52-55.
[13]	张守艳, 陈丹凤, 林榕. IMPACT模式护理对慢性射血分数保留心力衰竭患者遵医优良率的改善效果[J]. 心血管病防治知识, 2024, 14(8): 116-119.
[14]	戴剑, 彭芳展. 左卡尼汀对急性非ST段抬高型心肌梗死患者急诊PCI治疗的效果观察[J]. 心血管病防治知识, 2024, 14(7): 19-22.
[15]	林春华. 经冠状动脉微导管注射硝普钠联合PCI改善STEMI患者心功能的效果[J]. 心血管病防治知识, 2024, 14(7): 29-31.